[go: up one dir, main page]

PE20081106A1 - Comprimidos pediatricos de capecitabina - Google Patents

Comprimidos pediatricos de capecitabina

Info

Publication number
PE20081106A1
PE20081106A1 PE2007001349A PE2007001349A PE20081106A1 PE 20081106 A1 PE20081106 A1 PE 20081106A1 PE 2007001349 A PE2007001349 A PE 2007001349A PE 2007001349 A PE2007001349 A PE 2007001349A PE 20081106 A1 PE20081106 A1 PE 20081106A1
Authority
PE
Peru
Prior art keywords
pediatric
capecitabin
composition
pediatric tablets
tablets
Prior art date
Application number
PE2007001349A
Other languages
English (en)
Inventor
Maria Oksana Bachynsky
Navnit Hargovindas Shah
Mohammad Rashed
Martin Howard Infeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081106(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081106A1 publication Critical patent/PE20081106A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA ORAL, QUE CONTIENE COMO PRINCIPIO ACTIVO 5'-DESOXI-5-FLUORO-N-[(PENTILOXI)-CARBONIL]-CITIDINA (CAPECITABINA) ENTRE 50 MG Y 1500 MG, EL CUAL CONFORMA EL 10-50% DEL NUCLEO; SON EXCIPIENTES: CROSPOVIDONA, MANITOL, CELULOSA MICROCRISTALINA, HIDROXIPROPILMETILCELULOSA, ASPARTAMO, ENTRE OTROS. DICHA COMPOSICION SE DISGREGA EN AGUA A 37ºC EN MENOS DE 2 MINUTOS Y TIENE UNA DUREZA DE 8 A 13 UNIDADES DE FUERZA COBB SIENDO UTIL PARA PACIENTES QUE TIENEN DIFICULTAD PARA TRAGAR FORMAS FARMACEUTICAS CONVENCIONALES, COMO POBLACIONES PEDIATRICAS Y GERIATRICAS
PE2007001349A 2006-10-06 2007-10-04 Comprimidos pediatricos de capecitabina PE20081106A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85017406P 2006-10-06 2006-10-06
US95155707P 2007-07-24 2007-07-24

Publications (1)

Publication Number Publication Date
PE20081106A1 true PE20081106A1 (es) 2008-09-17

Family

ID=39186803

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001349A PE20081106A1 (es) 2006-10-06 2007-10-04 Comprimidos pediatricos de capecitabina

Country Status (30)

Country Link
US (2) US20080085310A1 (es)
EP (1) EP2073791B1 (es)
JP (1) JP5330248B2 (es)
KR (1) KR101177730B1 (es)
CN (1) CN101522168B (es)
AR (1) AR063138A1 (es)
AT (1) ATE492267T1 (es)
AU (1) AU2007304293A1 (es)
BR (1) BRPI0719241A2 (es)
CA (1) CA2664922C (es)
CL (1) CL2007002875A1 (es)
CO (1) CO6150122A2 (es)
CR (1) CR10668A (es)
CY (1) CY1111223T1 (es)
DE (1) DE602007011475D1 (es)
DK (1) DK2073791T3 (es)
HR (1) HRP20110113T1 (es)
IL (1) IL197767A0 (es)
MA (1) MA30779B1 (es)
MX (1) MX2009003317A (es)
MY (1) MY145637A (es)
NO (1) NO20090980L (es)
NZ (1) NZ575280A (es)
PE (1) PE20081106A1 (es)
PL (1) PL2073791T3 (es)
PT (1) PT2073791E (es)
RU (1) RU2455979C2 (es)
SI (1) SI2073791T1 (es)
TW (1) TW200825096A (es)
WO (1) WO2008040665A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TWI455733B (zh) * 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
CN103156877B (zh) * 2011-12-13 2015-11-25 深圳海王药业有限公司 一种卡培他滨速释微丸及其制备方法
CN102988320B (zh) * 2012-12-13 2014-04-16 哈药集团技术中心 一种卡培他滨分散片及其制备方法
CN104739800A (zh) * 2015-02-03 2015-07-01 吉林修正药业新药开发有限公司 一种卡培他滨片组合物及其制备方法
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
JP6866113B2 (ja) * 2016-11-01 2021-04-28 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤
JP6792418B2 (ja) * 2016-11-08 2020-11-25 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤の製造方法
IL298204A (en) * 2020-05-19 2023-01-01 Cellix Bio Private Ltd Pharmaceutical formulations and their preparation for cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
JPH0971523A (ja) * 1995-09-07 1997-03-18 Riyuukakusan:Kk 口腔内で崩壊性の速い錠剤
AU741992B2 (en) * 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
RU2135169C1 (ru) * 1998-12-02 1999-08-27 Государственное предприятие Казанское производственное химико-фармацевтическое объединение "Татхимфармпрепараты" Противовоспалительное, болеутоляющее, жаропонижающее лекарственное средство и способ его получения
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2790387B1 (fr) * 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
AU4278301A (en) * 2000-03-27 2001-10-08 Kyowa Hakko Kogyo Co. Ltd. Easy-to-take granule
JPWO2002069934A1 (ja) * 2001-03-06 2004-07-02 協和醗酵工業株式会社 口腔内速崩壊性製剤
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
DE102004028940A1 (de) * 2004-06-15 2006-01-12 Krka Tovarna Zdravil, D.D. Oral zerfallende pharmazeutische Zusammensetzung, die Risperidon enthält
ES2327195B1 (es) * 2005-04-12 2010-07-09 Elan Pharma International Limited Composiciones de liberacion modificada que comprenden un derivado de fluorocitidina para el tratamiento del cancer.

Also Published As

Publication number Publication date
AU2007304293A1 (en) 2008-04-10
RU2009116816A (ru) 2010-11-20
NZ575280A (en) 2012-03-30
MY145637A (en) 2012-03-15
MX2009003317A (es) 2009-04-09
HK1135905A1 (en) 2010-06-18
CA2664922C (en) 2015-06-30
CO6150122A2 (es) 2010-04-20
WO2008040665A3 (en) 2008-06-19
CN101522168B (zh) 2011-09-28
EP2073791B1 (en) 2010-12-22
US20150044287A1 (en) 2015-02-12
HRP20110113T1 (hr) 2011-03-31
KR20090045948A (ko) 2009-05-08
DE602007011475D1 (de) 2011-02-03
PT2073791E (pt) 2011-01-21
CN101522168A (zh) 2009-09-02
AR063138A1 (es) 2008-12-30
BRPI0719241A2 (pt) 2014-07-15
JP2010505791A (ja) 2010-02-25
IL197767A0 (en) 2009-12-24
NO20090980L (no) 2009-03-31
CA2664922A1 (en) 2008-04-10
CR10668A (es) 2009-04-29
WO2008040665A2 (en) 2008-04-10
DK2073791T3 (da) 2011-01-31
TW200825096A (en) 2008-06-16
PL2073791T3 (pl) 2011-05-31
CL2007002875A1 (es) 2008-01-25
SI2073791T1 (sl) 2011-04-29
KR101177730B1 (ko) 2012-09-07
ATE492267T1 (de) 2011-01-15
MA30779B1 (fr) 2009-10-01
US20080085310A1 (en) 2008-04-10
CY1111223T1 (el) 2015-06-11
JP5330248B2 (ja) 2013-10-30
RU2455979C2 (ru) 2012-07-20
EP2073791A2 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20120654A1 (es) Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
AR070731A1 (es) Composicion farmaceutica para farmacos poco solubles
UY32599A (es) Formulación oral sólida de abt-263
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
WO2011050206A3 (en) Compositions and methods for the treatment of sinonasal disorders
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
PE20081751A1 (es) Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor
ECSP044986A (es) Composicion farmaceutica que comprende lumiracoxib
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed